Abstract: Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and antiatherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin treatment and the prevention of cardiovascular disease, a high residual risk is observed in statin trials. This residual risk is partly explained by lipoprotein abnormalities other than LDL. Fenofi brate exerts a favorable effect on the atherogenic lipid profi le of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dyslipidemia. Fenofi brate may offer important treatment alternatives as a second-line therapy in several circumstances: in combination with a statin for patients with mixed dyslipidemias not at goals on statin monotherapy; in monotherapy for patients intolerant or with contraindication to statin therapy; and in combination with other drugs (ezetimibe, colesevelam) for patients with mixed dyslipidemias, known intolerance, or contraindication to statin and not at goals on fenofi brate monotherapy. However, the role of fenofi brate-statin therapy and of other therapies involving fenofi brate in cardiovascular risk reduction strategies remains to be established.
Around the world, cardiovascular disease (CVD) is the leading cause of deaths for adults (World Health Statistics 2008) . The most important modifi able cardiovascular risk factors are smoking, hypertension, dyslipidemia, obesity (mainly central) and hyperglycemia. These risk factors are often clustered, particularly for patients with type 2 diabetes and/or metabolic syndrome. Among dyslipoproteinemia, mixed or combined hyperlipidemia is a common disorder, occurring in about 30% of myocardial infarction (MI) survivors (Durrington 2003) . Mixed dyslipidemia is characterized by elevated levels of triglycerides (TG) and reduced high-density lipoprotein cholesterol (HDL-C), with or without elevated levels of low-density lipoprotein cholesterol (LDL-C). This atherogenic lipoprotein phenotype is usually associated with a preponderance of small, dense LDL particles and an elevated apolipoprotein B (ApoB) concentration. All the metabolic abnormalities of mixed dyslipidemia contribute to increase risk for CVD. Mixed dyslipidemia can be genetically determined such as in familial combined hyperlipidemia and is also the must frequent lipid disorder found in patients with type 2 diabetes and metabolic syndrome (Best and O'Neal 2000; Szapary and Rader 2004) . This review updates the management of mixed dyslipidemia and particularly on the clinical utility of fenofi brate in mixed dyslipidemia.
Management of mixed dyslipidemia
Mixed dyslipidemia is usually characterized by elevated LDL-C and TG and decreased HDL-C levels. Although plasma levels of LDL-C may be normal or only slightly above target levels, an increase in atherogenic small, dense LDL is a common feature, as well as elevated non-HDL-C and ApoB levels. Numerous landmark trials involving HMGCoA reductase inhibitors (statins) have fi rmly demonstrated that LDL-C lowering signifi cantly reduces total mortality and CVD morbidity and mortality (CTT Collaborators 2005) . Therefore, the use of statins has become the cornerstone of lipid lowering therapy in reducing the risk of CVD. Statins are indicated as fi rst-line therapy for patients for primary hypercholesterolemia and mixed dyslipidemia. Moreover recent trials comparing different statin treatments have shown that intensive LDL-C lowering regimens are signifi cantly more effective than moderate treatments in reducing coronary events and atherosclerotic progression (Nissen et al 2004; Cannon et al 2006) .
Elevated LDL-C is identifi ed as the primary target of lipid-lowering therapy by both US (NCEP ATP III 2001; Grundy et al 2004a) and European (European guidelines 2007; The Task Force on Diabetes 2007) guidelines. These guidelines specifi ed LDL-C of 100 mg/dL (2.6 mmol/L) as a minimal goal of treatment in high risk patients. For patients at very high risk, a new therapeutic option for LDL-C is below 70 to 80 mg/dL (Ͻ2 mmol/L). The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) recognized both low HDL-C (Ͻ40 mg/dL) and elevated TG (Ն150 mg/dL) as markers of increased CVD risk. Beyond lowering LDL-C, the NCEP ATP III introduced a secondary target of therapy, non-HDL-C, in patients with elevated TG. In some studies, non-HDL-C has been reported to be a stronger predictor of CVD risk than LDL-C (Cui et al 2001; Ridker et al 2005) . More recently, in a post hoc analysis of TNT and IDEAL trials (Kastelein et al 2008) , on-statin treatment levels of non-HDL-C and apolipoprotein B were more closely associated with cardiovascular outcome than LDL-C levels, supporting the use of non-HDL-C as a novel treatment target. The goal for non-HDL-C at any level of risk is 30 mg/dL higher than the LDL-C treatment goal. Thus, in patients with mixed dyslipidemia and very high risk (ie, with CVD and diabetes or the metabolic syndrome (Grundy et al 2004a) who have an LDL-C goal of 70 mg/dL, the non-HDL-C goal is 100 mg/dL. The coronary risk is also associated with mildly elevated (150-500 mg/dL) plasma TG level. Very high levels of TG (Ͼ500 mg/dL) are a risk for acute pancreatitis.
In high risk patients with mixed dyslipidemia, an ideal treatment should deal with the global spectrum of the atherogenic lipid triad (high LDL-C, low HDL-C and high TG). High levels of LDL-C could be effectively controlled with a statin. However statin therapy may be limited by the failure to reach non-HDL-C goals and sometimes by intolerance or poor response in monotherapy. Several considerations have led to increased interest in non-statin options for correction of mixed dyslipidemia: -Low HDL-C is associated with increased CVD risk (Gordon et al 1977 (Gordon et al , 1989 . The Framingham study indicated a clear relationship between low HDL-C levels and increased risk of coronary disease, irrespective of LDL-C levels (Gordon et al 1977) . In a meta-analysis of four large prospective studies (Gordon et al 1989) , every 1 mg/dL decrease in HDL-C is associated with increased risk of coronary heart disease (CHD), differently in males and females (2% males and 3% females), independent of other risk factors, including LDL-C levels. -Even if TG have been a controversial risk factor, recent epidemiologic evidences have demonstrated that elevated TG independently predicts CVD. A recent meta-analysis of 29 prospective studies enrolling 262,525 subjects indicated a strong and highly signifi cant association between TG values and CHD risk (Sarwar et al 2007) . Two additional studies have corroborated these fi ndings (Bansal et al 2007; Nordestgaard et al 2007) , both studies supporting the concept that non-fasting TG levels may strongly predicts the CVD risk (McBride 2007) . In mixed dyslipidemia, post-prandial triglyceride-rich lipoproteins are typically increased with a delay in the clearance of these lipoprotein particles and a prolonged exposure. -Although statins are clearly effective in lowering LDL-C levels, this class of drugs appear to have more modest effects in terms of raising HDL-C and lowering TG. Statins have been reported to raise HDL-C levels by 5% to 15% and to lower TG by 7% to 30% (NCEP ATP III 2001 ). -Finally in landmark statin clinical trials, high "residual" CVD risk can be partly explained by the presence of lipoprotein abnormalities other than LDL. Indeed, subjects treated with a statin but who had low HDL-C levels remained at a greater CVD risk than those with normal or high HDL-C levels. In a recent post-hoc analysis of the Treating to New Targets (TNT) trial, levels of HDL-C were inversely related to the risk of major CVD events among CHD patients receiving statin treatment (Barter et al 2007) . Even in patients with LDL-C at or below the optional treatment target of 70 mg/dL, those who were in the lowest HDL-C quintile had a significantly increased CVD risk compared with those in the highest HDL-C quintile (Barter et al 2007) . Interestingly
Fenofi brate in mixed dyslipidemias a similar fi nding has been found for TG levels in a complementary analysis of PROVE-IT TIMI-22 trial (Miller et al 2008) : compared with individuals who achieved low levels of both LDL-C (Ͻ70 mg/dL) and TG (Ͻ150 mg/dL), patients with higher levels of ontreatment LDL-C and/or TG had signifi cantly elevated risk of CHD events. On-treatment TG Ͻ150 mg/dL was independently associated with a lower risk of recurrent CHD effects. Conversely, a number of studies have demonstrated that treatment with fi brates or niacin (with or without a statin) improves the atherogenic lipoprotein profi le and/or reduces cardiovascular morbidity and mortality. Among these drugs, this review only reports arguments for a clinical utility of fenofi brate.
Mechanism of action of fenofi brate
Fenofi brate belongs to a class of drugs that exert their effects by activating the peroxisome proliferator-activated receptor α (PPARα), a transcription factor that regulates lipid metabolism via a number of routes. Activated PPARα stimulates the expression of genes encoding various enzymes that regulate fatty acid and lipoprotein metabolism (Fruchart et al 2001; Fazio and Linton 2004; Keating and Croom 2007) . Fenofi brate stimulated the oxidation of free fatty acids in the liver. This promotion of the β-oxidation of fatty acids reduced the availability of fatty acids for very-low density lipoprotein (VLDL) synthesis and secretion. Fenofi brate also increased the expression of the gene for lipoprotein lipase and decreases ApoC-III expression in the liver. Thus, fenofi brate lowered the concentration of TG both by reducing the rate of synthesis and increasing the rate of hydrolysis of triglyceride-rich lipoproteins (Staels et al 1998; Keating and Croom 2007) . Moreover, fenofi brate treatment reduced the proportion of small, dense LDL, with the formation of larger, less dense LDL particles with a higher affi nity for the LDL receptor and thus catabolized more rapidly (Chapman 2006) . PPARα activation with fenofi brate also increased expression of the genes for both ApoA-I and ApoA-II, decreased the cholesteryl ester transfer protein-mediated transfer of cholesterol from HDL to VLDL, enhanced cell cholesterol effl ux by induction of cell ABCA1 expression and decreased SR-B1 in the liver. All these effects contribute to the increase of plasma HDL-C concentrations (Guerin et al 1996; Chinetti et al 2001; Mardones et al 2003; Fruchart and Duriez 2006) .
In addition to the lipid-modifying activity, fenofi brate also had numerous pleiotropic effects mediated by PPARα activation (Staels et al 1998; Paumelle and Staels 2008) : fenofi brate improved endothelial function (Playford et al 2002; Capell et al 2003; Koh et al 2005) and exerted anti-infl ammatory activities (Zambon et al 2006; Rosenson et al 2008) as evidenced by a reduction in CRP as well as a number of cytokines (eg, IL-6, TNF-alpha) In patients with metabolic syndrome and elevated TG, fenofibrate reduced whole blood production of infl ammatory cytokines and hepaticsynthesized infl ammatory proteins, and the anti-infl ammatory effects of fenofi brate involve VLDL-and LDL-mediated pathways (Rosenson et al 2008) . Fenofi brate also decreased procoagulant factors such as fi brinogen and plasminogen activator inhibitor-1 (Kaneko et al 2002; Maison et al 2002) and reduced monocyte chemoattractant protein-1 (Keating and Ormrod 2002; Paumelle and Staels 2008) . Among fi brates, only fenofi brate signifi cantly reduced uric acid levels (Liamis et al 1999; Keating and Ormrod 2002) .
In contrast, fenofi brate therapy induced two potential deleterious effects: an increase in creatinine (Keating and Ormrod 2002; Tsimichodimos et al 2002) and homocysteine levels (Keating and Ormrod 2002; Dierkes et al 2003) . Whether these effects on creatinine and homocysteine are of clinical importance remains to be determined. Creatinine rises was not associated with an alteration in renal function, as measured by glomerular fi ltration rate (Hottelart et al 2002) . The creatinine elevation associated with fenofi brate treatment is fully reversible within a few weeks of ceasing therapy (The FIELD study investigators 2005), also suggesting an absence of permanent renal damage.
The potential of monotherapy with fenofi brate in the treatment of patients with primary dyslipidemia has been well established in numerous, placebo-controlled and comparative trials (Adkins and Faulds 1997; Keating and Ormrod 2002) . The effect of fenofi brate on the concentration of plasma lipids is largely infl uenced by the baseline lipid levels. Fenofi brate therapy was consistently associated with a substantial decreases of serum TG by 20% to 50%, usually directly proportional to the baseline TG levels. Fenofi brate increased HDL-C levels by 10% to 25%, to a degree directly dependent of baseline TG and HDL-C levels. Fenofi brate had widely variable effects on LDL-C levels mainly dependent of the type of dylipidemia. For example, fenofi brate may decrease LDL-C by 20% in patients with normal TG levels, but generally produces less reduction in LDL-C in patients with mixed dyslipidemia. Patients with severe hypertriglyceridemia and low levels of LDL-C may raise their LDL-C levels during fenofi brate treatment, possibly as a result of an accelerated catabolism of triglyceride-rich lipoproteins, leading to an increased LDL conversion and an increased LDL particle size. This increase in LDL size may constitute an antiatherogenic mechanism. 
Clinical utility of fenofi brate in mixed dyslipidemia Clinical effi cacy in monotherapy
A meta-analysis of randomized fi brate trials (1,457 patients receiving fenofi brate) realized across a range of populations, found that fenofibrate decreased LDL-C and TG respectively by 11% and 40% and increased HDL-C by 10% (Birjmohun et al 2005) .
Although the effect of fenofi brate on LDL-C in these studies was variable, it was generally smaller than that achieved with statins. Two recent trials (Farnier et al 2005; provided data on the effi cacy of fenofi brate monotherapy in large populations of patients with mixed dyslipidemia: in these trials, TG decreased by 43.2% and 41.3%, HDL-C increased by 18.8% and 18.2%, LDL-C decreased by 5.5% and 15.7%, and non-HDL-C decreased by 16.2% and 21.0% (Farnier et al 2005; . The effects on ApoB were in agreement with the evolution of non-HDL-C levels: ApoB levels decreased by 15.2% and 20.1%. ApoA-I levels were increased by 8.4% and 10.8% (Farnier et al 2005; . Finally these trials have confi rmed a large and signifi cant shift in LDL size with a decrease in the proportion of small, dense LDL during fenofi brate treatment. In summary, fenofibrate has a favorable action on all the lipoprotein abnormalities present in patients with mixed dyslipidemia.
This pattern of mixed dyslipidemia with high TG, low HDL-C and preponderance of small dense LDL is usually observed in type 2 diabetes and metabolic syndrome. Presumably to follow-up on the favorable effects of gemfibrozil treated diabetic patients in Helsinki Heart Study (HHS) and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) study, the potential role of fenofi brate for CVD risk reduction has only been evaluated in type 2 diabetes, but not specifi cally type 2 diabetic patients with mixed dyslipidemia.
In the Diabetes Atherosclerosis Intervention Study (DAIS 2001) , 418 diabetic men and women were randomized to fenofi brate or placebo for 3 years. Baseline lipids were LDL-C of 132 mg/dL, TG of 221 mg/dL, and HDL-C of 40 mg/dL. Fenofi brate lowered LDL-C by 6% and TG by 28%, and raised HDL-C by 7%. Fenofi brate slowed the angiographic progression of coronary atherosclerosis: the progression of focal coronary atheroma was 40% less in the fenofi brate group compared with placebo, without signifi cant effect on diffuse atheroma. Interestingly, although the study was not powered to look at clinical events, there was a non signifi cant 23% reduction in CVD events. These effects seemed to be explained not only by the changes in HDL-C, LDL-C and TG levels, but also by a signifi cant increase in LDL particle size (Vakkilainen et al 2003) . Additionally, fenofi brate reduced the incidence of microalbuminuria by 54% (Ansquer et al 2005) . In DAIS, the increase of homocysteine did not alter the benefi cial effect of fenofi brate (Genest et al 2004) .
The Fenofi brate Intervention and Event Lowering in Diabetes (FIELD) was the fi rst large landmark cardiovascular event-based trial with fenofi brate (The FIELD study investigators 2005). FIELD was a 5-year, randomized, placebocontrolled, double-blind study of the effi cacy and safety of fenofi brate 200 mg/day in 9795 type 2 diabetic patients with (22%) or without (78%) previous CVD. Mean baseline lipids were LDL-C of 119 mg/dL, TG of 153 mg/dL, and HDL-C of 43 mg/dL. Unfortunately, only 21% of patients had a marked dyslipidemia defi ned (for comparison with other fi brates trials) by TG Ն 200 mg/dL and low HDL-C Ͻ40 mg/dL in men and Ͻ50 mg/dL in women (Scott et al 2007) . At 4 months and study close, fenofi brate decreased respectively TG by 29% and 22%, LDL-C by 12% and 6% and increased HDL-C by 5% and 1%. Fenofi brate treatment did not have a signifi cant effect on the primary end point (CHD death or non-fatal MI) reduced by only 11% (p = 0.16). There was, however, a signifi cant reduction (−11%, p = 0.035) in the secondary end point of total CVD events (a composite of CVD death, MI, stroke, and coronary or carotid revascularization), largely driven by signifi cant reductions in non-fatal MI (−24%, p = 0.01) and coronary revascularization (−21%, p = 0.003). There was a non-signifi cant increase in CHD death in the fenofi brate group. The FIELD investigators also reported a signifi cant 20% reduction of all MI events (p = 0.006) and a signifi cant 38% reduction in the risk of non-traumatic amputations (p = 0.011) with fenofi brate (Burgess et al 2007) . Fenofi brate treatment was also associated with signifi cant reductions in the need for retinal laser therapy and decreased progression/increased regression of albuminuria (The FIELD study investigators 2005). The global results of FIELD have been considered as disappointing event if the overall CVD event results were positive in several regards.
Some explanations can be proposed to explain the FIELD results: the higher rate of statin use in the placebo group (36% among placebo patients by close of study versus 19% in the fenofi brate arm) may play a role. Among fenofi brate patients not receiving off-trial lipid treatment, the CVD composite end point was signifi cantly reduced by 19%. The poor effect of fenofi brate in reducing CVD events, more particularly in secondary prevention, could also be explained by the signifi cant increase of homocysteine levels. It has been shown that gemfi brozil increased plasma homocysteine less than fenofi brate (Dierkes et al 2003; Syvanne et al 2004) and this difference could explain the better clinical benefi t of gemfi brozil in the VA-HIT (Robins et al 2001; Rubins et al 2002) and HHS (Frick et al 1987) . Another hypothesis to explain the FIELD results is the modest effects of fenofi brate on lipid parameters; particularly the declining effect on HDL-C overtime could also be due to the fact to elevated homocysteine has been reported to reduce the ApoA-I expression (Mikael et al 2006) .
More convincing, the relative lack of favorable effects in FIELD may be related to the selected population. Fibrates reduce CVD effectively in patients with insulin resistance/ overweight people with high TG and low HDL-C (Barter and Rye 2008) . In FIELD, the baseline TG was lower and the HDL-C was higher than in HHS or VA-HIT, with a lower TG/HDL-C ratio (4.05) than in VA-HIT (higher ratio of 5.37). New complementary analyses recently reported (Scott et al 2007) have provided important data on the clinical utility of fenofi brate in mixed dyslipidemia: in the subgroup of 2,014 patients with low HDL-C and TG Ͼ 200 mg/dL, fenofi brate treatment induced a signifi cant reduction of CVD events (13.5% in the fenofi brate group versus 17.8% in the placebo group, HR 0.74, p = 0.007). This highly signifi cant effect corresponds to a 4.3% absolute risk reduction, with a number need to treat of 23 to avoid 1 or more CVD events. The benefi cial effect of fenofi brate on macrovascular events appears larger among type 2 diabetic subjects with mixed dyslipidemia (Scott et al 2007) .
Fenofi brate was generally well tolerated. A meta-analysis of 53 trials using fi brates has not shown any increase in non coronary death or cancer (Birjmohun et al 2005) . The most frequent adverse effects were gastrointestinal symptoms, skin reactions and musculoskeletal symptoms (Birjmohun et al 2005) . Some cases of liver function test and creatine phosphokinase abnormalities have been reported (Keating and Ormrod 2002; Keating and Croom 2007) . In the FIELD trial, it has been also observed a slight but signifi cant increase in pancreatitis (0.8% in fenofi brate group versus 0.5% in placebo group) and pulmonary embolism (1.1% versus 0.7%), and a non signifi cant increase in deep vein thrombosis (1.4% versus 1.0%). The excess of pancreatitis may be due to the increased lithogenicity of bile. The increased risk of venous thrombotic events may be related to the increased homocysteine level, a risk factor for thrombosis (Undas et al 2005) . Overall, in FIELD, rhabdomyolysis only occurred in three fenofi brate recipients and one placebo recipient, and all cases were fully resolved.
Fenofi brate is contraindicated in patients with hepatic or several renal dysfunction, pre-existing gallbladder disease, primary biliary cirrhosis or unexplained persistent liver function abnormalities. Fenofi brate potentiates the anticoagulant activity of coumarin and there is a warning on the concomitant use of fenofi brate and cyclosporine.
Clinical effi cacy in combination with statins
Guidelines suggest both fi brates and niacin as additions to statin therapy in high risk patients with persistently low levels of HDL-C and elevated triglycerides (Grundy et al 2004a; Buse et al 2007;  The Task Force on Diabetes 2007). Updated guidelines from the NCEP ATP III recognize the potential of the statin-fi brate and statin-niacin combination therapies in patients with mixed dyslipidemia and CHD or CHD risk equivalents (Stone et al 2005) .
Given the complementary pharmacologic profi les of fi brates and statins, greater clinical benefi t may be expected with combination therapy. However the use of fi brate/statin combination therapy has been rapidly restricted due to safety concerns, mainly an increased risk of myopathy and rhabdomyolysis (Shek and Ferrill 2001; Farnier 2003) . Several reviews have examined the benefi cial effects and the safety of a statin-fi brate combination therapy (Shek and Ferrill 2001; Farnier 2003; Wierzbicki et al 2003; Stefanutti et al 2004; Corsini et al 2005) . In summary, the available evidence on safety clearly indicates differences in the risk of myopathy and rhabdomyolysis between fi brates (Alsheikh-Ali et al 2004; Jones and Davidson 2005) . In combination with a statin, rhabdomyolysis has been reported to be 15-fold (Jones and Davidson 2005) and 33-fold (Alsheikh-Ali et al 2004) higher with gemfi brozil than with fenofi brate. Moreover the risk was particularly elevated when cerivastatin was use in combination with gemfi brozil (Chang et al 2004; Graham et al 2004; Jones and Davidson 2005) . The pharmacokinetic interactions between statins and fi brates have been carefully studied (Prueksaritanont et al 2002a; Corsini et al 2005) . The mechanism for the higher rate of adverse interaction of gemfi brozil versus fenofi brate with statins appears mainly to be interference with statin glucuronidation by gemfibrozil. In vitro studies have demonstrated that gemfi brozil interacts with the same family of glucuronidation enzymes that are involved in statin metabolism (Prueksaritanont et al 2002a, b) . In contrast, fenofi brate was metabolized by different glucuronidation enzymes than those involved in statin metabolism (Prueksaritanont et al 2002b) . Therefore, gemfi brozil causes a 2-to 6-fold increase in the statin AUC All these data suggest that fenofi brate may be the preferred fi brate for use in combination with statin and guidelines recommend fenofi brate as the fi brate of choice for high-risk statin-treated patients with mixed dyslipidemia (Grundy et al 2004b) . Fenofi brate may be added to a statin when mixed dyslipidemia responds inadequately with monotherapy, although use of lower statin doses has been recommended in this case (Davidson et al 2007) .
The results of clinical studies support the effi cacy of fenofi brate-statin therapy in patients with mixed dyslipidemia (Ellen and McPherson 1998; Athyros et al 2002; Vega et al 2003; Durrington et al 2004; Grundy et al 2005) . For example, in the SAFARI trial (Grundy et al 2005) , 619 patients with mixed dyslipidemia (TG from 150 to 500 mg/dL and LDL-C higher than 130 mg/dL) were treated with either simvastatin 20 mg/d or the combination of simvastatin 20 mg/d plus fenofi brate 160 mg/d for 12 weeks. The combined treatment was associated with signifi cantly greater changes compared with simvastatin alone in TG (−43.0% versus −20.1%), LDL-C (−31.2% versus −25.8%), non-HDL-C (−35.3% versus −26.1%), and HDL-C (+18.6% versus +9.7%). In addition, combination therapy induced a signifi cant shift from small, dense LDL particles to larger, more buoyant LDL particles (Grundy et al 2005) .
The same benefi cial effect on LDL subfractions has been observed in the DIACOR study in the group of patients with type 2 diabetes and mixed dyslipidemia receiving the combination of simvastatin 20 mg/d and fenofi brate 160 mg/d (May et al 2008) . The DIACOR trial has also shown that combination therapy has greater anti-infl ammatory effects than either form of monotherapy (Muhlestein et al 2006) , probably in relation with the cross-talk between statins and PPARα agonists regarding pleiotropic effects (Paumelle and Staels 2008) . Several trials are ongoing to evaluate more precisely the complementary benefi cial effects of fenofi brate for patients with mixed dyslipidemia not at goals on statin therapy.
All these data may support the use of fenofi brate-statin combination therapy to achieve a global lipid and vascular control and suggest that atherosclerosis and CVD benefi ts may be greater with combination therapy, but direct evidence of these benefi ts is not yet available. Hopefully, the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study was designed to evaluate whether adding fenofi brate to simvastatin can reduce CVD risk beyond the risk reduction with simvastatin alone in type 2 diabetic patients (The ACCORD Study Group 2007; Ginsberg et al 2007) .
Clinical effi cacy in combination therapy with other agents
Although statins are the drug of fi rst choice in patients with mixed dyslipidemia, the use of statins may be limited by intolerance or poor response in monotherapy.
In patients who are unable to tolerate statin therapy, two alternative combination therapies with fenofi brate can be proposed at patients with mixed dyslipidemia, either fenofi brate-ezetimibe or fenofi brate-colesevelam. The effi cacy and safety of fenofi brate plus ezetimibe combination therapy has been evaluated in 625 patients with mixed dyslipidemia [TG from 200 to 500 mg/dL, LDL-C from 130 to 220 mg/dL (100-180 mg/dL in patients with diabetes)] (Farnier et al 2005; McKenney et al 2006) randomized to received one of the four daily treatments: placebo, ezetimibe 10 mg, fenofi brate 160 mg and fenofi brate 160 mg + ezetimibe 10 mg during 12 weeks. The complementary effects of fenofi brate and ezetimibe improve the overall atherogenic lipid profi le, with decreases in LDL-C of 20.4%, non-HDL-C of 30.4%, TG of 44.0%, and increase in HDL-C of 19.0% (Farnier et al 2005) . Moreover, the co-administration of fenofi brate and ezetimibe produced complementary and favorable changes in lipoprotein subfractions, promoting a shift in the LDL particle distribution profi le toward larger, more buoyant particles (Farnier et al 2005; Tribble et al 2008) . After completing the 12-week, randomized, double-blind base study, 576 patients entered in a 48-week, double-blind extension study, during which they received fenofi brate or fenofi brate plus ezetimibe (McKenney et al 2006) . Improvements from baseline in LDL-C (−22.0% versus −8.6%), non-HDL-C (−31.6% versus −19.4%), TG (−46.0% versus −41.8%) and HDL-C (20.9% versus 17.8%) levels were signifi cantly greater with fenofibrate-ezetimibe combination therapy than with fenofi brate alone. The combination of ezetimibe plus fenofi brate was well tolerated during both the base study (Farnier et al 2005) and the extension study (McKenney et al 2006) . In the base study, one patient receiving combination therapy was discontinued after being diagnosed with cholelithiasis and subsequent cholecystectomy. In the extension study, the proportion of patients with cholecystectomy was not significantly different between treatments, but this study was not designed to assess this infrequent biliary adverse event. It has been reported that fenofi brate may increase cholesterol excretion into bile and ezetimibe has inconsistent effects on biliary cholesterol in animal models (Farnier 2007) .
Another alternative to statin therapy is a bile acid sequestrant (BAS) combined with a fi brate. Colesevelam has become the preferred BAS because it is well-tolerated compared to older BAS and lowers LDL-C levels an average of 15% to 18%. The complementary effi cacy of colesevelam added to fenofi brate has been evaluated in 129 patients with mixed dyslipidemia treated 8 weeks by fenofi brate 160 mg/d, then randomized to receive either colesevelam 3.75 g/d or placebo (McKenney et al 2005) . Compared with fenofi brate monotherapy, the combination of fenofi brate and colesevelam signifi cantly reduced LDL-C (−17.0%) and non-HDL-C (−21.0%) from baseline, without affecting the TG-lowering or HDL-C raising effects of fenofi brate (McKenney et al 2005) .
Finally in patients with severe mixed dyslipidemia or poor responders to statin monotherapy, a new option is a triple therapy using statin, ezetimibe and fenofi brate. The effi cacy of the co-administration of ezetimibe/simvastatin 10/20 mg + fenofibrate 160 mg has been evaluated in 611 patients with mixed dyslipidemia (TG from 150 to 500 mg/dL, LDL-C from 130 to 220 mg/dL [100-180 mg/dL in patients with diabetes]) randomized to receive one of the four treatments ezetimibe/simvastatin 10/20 mg + fenofi brate 160 mg, ezetimibe 10/20 mg, fenofi brate 160 mg, or placebo for 12 weeks . The triple therapy improved the overall atherogenic lipid profi le (−46% for LDL-C, −50% for TG and non-HDL-C, −45% for ApoB, +19% for HDL-C) with a signifi cant shift of small, dense LDL to larger particles . Although the co-administration of fenofi brate and ezetimibe/simvastatin was well tolerated in this short-term study, the long-term safety and clinical outcome benefi ts remain to be determined.
Rational prescribing of fenofi brate in mixed dyslipidemias
Although statins are indicated as fi rst-line therapy for patients with mixed dyslipidemia, statin treatment may be limited by the failure to reach LDL-C and non-HDL-C targets and by intolerance or poor-response in monotherapy. Moreover, many patients remain at risk of CVD despite having LDL-C levels below recommended targets. Thus, increasing attention is being focused on other lipoprotein fractions such as HDL and triglycerides, as potential targets of therapy. There is recent evidence that abnormalities of the triglyceride-HDL axis are especially associated with adverse cardiovascular outcomes. In FIELD, fenofi brate reduced CVD effectively in patients with insulin resistance, low HDL-C, and high TG. However, prescribing recommendations are constrained by a lack of clinical trial evidence of fenofi brate-statin therapy. Nevertheless, it is possible to propose a rational prescribing of fenofi brate in mixed dyslipidemia: 1. For high-risk patients not at their non-HDL-C goals and with high TG and/or low HDL-C levels, a statinfenofi brate combination therapy can be required to control all lipid abnormalities. In light of the increasing prevalence of diabetes and the metabolic syndrome, the clinical use of fenofi brate combined with a statin may be likely to increase. Data from prospective outcome studies are required to evaluate the benefi ts of this approach. In severe mixed dyslipidemia, when the LDL-C and non-HDL-C goals are not reached with a usual dose of statin and fenofi brate, a triple therapy with a statin, fenofi brate, and ezetimibe can be used to avoid the highest statin doses and with the same caution as statinfenofi brate therapy. 2. For patients with intolerance to statin therapy or if a statin is inappropriate or contraindicated, fenofi brate monotherapy is indicated in mixed dyslipidemia. However, particularly for high risk patients, the LDL-C and/or non-HDL-C goals are often not attained with fenofi brate alone. A combination of fenofi brate wth ezetimibe or colesevelam can be useful for these patients.
In conclusion, despite the impressive benefi ts achieved by LDL-C lowering using statins, there are compelling reasons to consider other lipoprotein abnormalities present in mixed dyslipidemia as risk factors. Fenofi brate has a favorable effect on the global atherogenic lipoprotein profi le and may offer important treatment alternatives as second-line therapy.
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